In this study, we have used the human BV173 and the mouse BaF3/Bcr-Abl-expressing cell lines as model systems to investigate the molecular mechanisms whereby STI571 and FoxO3a regulate Bim expression and apoptosis. FoxO3a lies downstream of Bcr-Abl signalling and is constitutively phosphorylated in the Bcr-Ablpositive BV173 and BaF3/Bcr-Abl cells. Inhibition of Bcr-Abl kinase by STI571 results in FoxO3a activation, induction of Bim expression and apoptosis. Using reporter gene assays, we demonstrate that STI571 and FoxO3a activate Bim transcription through a FoxO-binding site (FHRE) located within the promoter. This was verified by DNA pull-down and chromatin immunoprecipitation analyses. We find that conditional activation of FoxO3a leads to induction of Bim expression and apoptosis. Conversely, silencing of FoxO3a in Bcr-Abl-expressing cells abolishes STI571-mediated Bim induction and apoptosis. Together, the results presented clearly confirm FoxO3a as a key regulator of apoptosis induced by STI571, and show that Bim is a direct transcriptional target of FoxO3a that mediates the STI571-induced apoptosis. Thus, STI571 induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE in the promoter to activate Bim expression and apoptosis.
Introduction
Chronic myelogenous leukaemia (CML) is a malignant clonal haematopoietic stem cell disorder characterized by the presence of the Philadelphia (Ph) chromosome. The Ph chromosome originates from a reciprocal translocation between the long arms of chromosomes 9 and 22, culminating in the fusion of a truncated Bcr gene to 5 0 sequences of the c-Abl gene (Epner and Koeffler, 1990) . The resulting Bcr-Abl genes give rise to chimeric Bcr-Abl proteins of 230, 210 and 185 kDa. These Bcr-Abl proteins (p230, p210 and p185, respectively) with constitutively active tyrosine kinase activity (Lugo et al., 1990) are causative for the development of CML and Ph-positive acute lymphoblastic leukaemia (Ph þ ALL) (Faderl et al., 1999) . The p210 Bcr-Abl is found in 95% of CML and 20% of Ph þ ALL (Hariharan and Adams, 1987; Ramakrishnan and Rosenberg, 1989) , while the p185 protein is detected in 10% of Ph þ ALL (Chan et al., 1987) . The p230 form is found predominantly in the rare Ph þ chronic neutrophilic leukaemia (CNL) (Haskovec et al., 1998; Li et al., 1999) .
Both normal and malignant haematopoietic cells depend on cytokine(s) for their continued growth and survival (Williams et al., 1990; Kinoshita et al., 1995) . In CML, the survival signals are also provided by the constitutively active Bcr-Abl kinase, enabling the BcrAbl-expressing cells to remain viable in the presence of limited cytokines. The phosphatidylinositol 3-kinase (PI 3-K)/PKB signalling pathway is one of the downstream signalling cascades hyperactivated by the constitutively active Bcr-Abl kinase and has been demonstrated to be essential for the antiapoptotic functions of Bcr-Abl. The Bcr-Abl tyrosine kinase has been shown to activate PI 3-K by a mechanism that requires binding of Bcr-Abl to p85, the regulatory subunit of PI 3-K (Skorski et al., 1995) .
PI 3-Ks are a group of lipid kinases that mediate the phosphorylation of the inositol ring of phosphoinositides at position 3. The ubiquitously expressed class I PI 3-Ks consist of heterodimers comprising of a p110 catalytic and a p85 regulatory subunit. The class I PI 3-Ks are involved in a variety of cellular processes, including cell proliferation, survival, metabolism, differentiation, cytoskeletal organization and membrane trafficking (Leevers et al., 1999) . When activated, these PI 3-Ks convert the substrate phosphatidylinositol-4,5-bisphosphate (PI 4,5-P 2 ) into the second messenger phosphatidylinositol 3,4,5-triphosphate (PI 3, 4, ). Accumulation of PI 3,4,5-P 3 causes the phosphorylation and activation of the serine/threonine kinase PKB (also termed Akt), as well as the phosphorylation and inactivation of downstream PKB targets, including Bad, GSK3 and FoxO proteins, which have a negative role in cell survival (Mitsiades et al., 2004) . FoxO (Forkhead box, class O) is a newly characterized subfamily of the Forkhead/winged helix (Fox) group of transcription factors, which play a predominant role in mediating the proliferative and survival function of the PI 3-K/PKB signalling pathway Burgering and Medema, 2003) . Three FoxO proteins, FoxO1 (FKHR), FoxO3a (FKHR-L1), and FoxO4 (AFX), have been identified in mammals, and they regulate the expression of many genes involved in cell cycle arrest, apoptosis, differentiation and stress responses. Phosphorylation of FoxO proteins by PKB results in their transcriptional inactivation and nuclear exclusion, which are believed to be mediated by the 14-3-3 chaperone proteins. Recently, we have identified cell cycle regulators, including cyclin D1 and D2 (Schmidt et al., 2002) , p27 KIP1 (Dijkers et al., 2000a) and p130 as gene targets for the FoxO proteins. We have shown that while the negative cell cycle regulators p27 KIP1 and p130 are direct transcriptional targets of FoxO proteins (Dijkers et al., 2000a; Kops et al., 2002) , FoxOs negatively regulate cyclin D2 through the transcriptional repressor Bcl-6 (Ferna´ndez de Mattos et al., 2004) .
STI571 (also called Gleevec and Imatinib mesylate) has proved to be effective as a first-line treatment for CML and Ph þ ALL patients Tauchi et al., 2004) . Nevertheless, relapses often occur after the initial positive responses, and the acquired resistance is usually associated with mutations and/or amplifications of the Bcr-Abl gene. Targeting the signalling cascades downstream of Bcr-Abl kinase may yet prove to be a more effective and long-term therapeutic strategy, and this will come from better understanding of the downstream Bcr-Abl signalling pathways, which control cell growth and survival. Previous data have suggested that the proapoptotic BH3-only member of the Bcl-2 family, Bim, plays an important role in the apoptosis of normal and malignant haematopoietic progenitors and that Bcr-Abl supports cell survival in part through downregulation of Bim expression (Kuribara et al., 2004a) . Bim, like other BH3-only Bcl-2 proteins, mediates apoptosis through promoting mitochondrial cytochrome c release, which in turn activates caspase 9, caspase 3 and eventually the downstream cell death machinery (Dijkers et al., 2000b; Harada and Grant, 2003) . Bim exists in three major isoforms (BimS, BimL and BimEL) that are generated by alternative splicing of a number of transcripts. Bim has recently been shown to be a downstream target of the FoxO transcription factor in a number of cell systems (Dijkers et al., 2000b; Stahl et al., 2002; Gilley et al., 2003; Sunters et al., 2003; Scheijen et al., 2004) ; however, the exact mechanism by which FoxO regulates Bim expression and their roles in STI571-induced apoptosis in Bcr-Abl-expressing cells has not been throughly elucidated. Here, using the human lymphoid CML cell line BV173 and the Bcr-Abl-transduced mouse pro-B BaF3 cell line, we show that both FoxO3a and Bim are essential mediators of apoptosis induced by STI571 in Bcr-Abl-expressing cells. Moreover, we demonstrate evidently that Bim is a direct transcriptional target of FoxO3a and that FoxO3a activates Bim expression through binding to a FoxO consensus site on the bim promoter.
Materials and methods

Cell culture
The human lymphoid CML cell line BV173 and the mouse BaF3/Bcr-Abl parental (Deininger et al., 2001; Parada et al., 2001) and derived cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 100 U/ml penicillin/ streptomycin. All experiments were performed on exponentially growing cells kept at low concentrations (i.e. o1 Â 10 6 / ml). To induce apoptosis, STI571 was added to the culture medium to give a final concentration of 5 mM. The BaF3/BcrAbl Á FoxO3a(A3):ER cells were generated by infecting BaF3/ Bcr-Abl cells with the retrovirus expressing the pBabe-puro-FKHR-L1.A3 . The infected cells were selected for 2 weeks on 200 mg/ml of puromycin (Sigma, Poole, UK). 4-OHT (Sigma) was added to the cells at a final concentration of 200 nM to activate the FoxO3a(A3):ER fusion protein. The BaF3/Bcr-Abl cell line has previously been described . STI571 was provided by Dr Elizabeth Buchdunger, Novartis, Switzerland.
Plasmid constructs
The FoxO3a expression vectors pLPC-FoxO3a(wt) and pLPCFoxO3a(A3) were derived from pECE-FKHR-L1(wt) and pECE-FKHR-L1(A3), respectively (Brunet et al., 1999) . The cDNAs were excised from the pECE-FKHR-L1(wt) and pECE-FKHR-L1(A3) by HindIII and XbaI restriction digestion and subcloned into the retroviral pLPC vector (de Stanchina et al., 1998) . Based on the published mouse bim promoter sequence (Bouillet et al., 2001 ), a 785 base-pair (bp) fragment of the human bim promoter, containing a single inverse Forkhead box TAAACAC (nucleotide À170/À164 relative to the trancription start of the promoter, Figure 2a ), was amplified from BV173 cells genomic DNA by PCR using the human promoter primers: 5 0 -AAGCTTCCCGCCCTCA CCCGGGA-3 0 and 5 0 -GAGCTCCAACAAACTGCAGACC-3 0 cloned in pGEM-T easy vector (Promega, Southampton, UK) and validated by sequencing. The human bim promoter was then mutated to introduce an EcoRI restriction site in the core of the Forkhead box using the following primers: 5 0 -TTACTCCGGAATTCACGCCAGGGA-3 0 and 5 0 -TCCCTG GCGTGAATTCCGGAGTAA-3 0 . Subsequently, a double PCR was performed using the human bim promoter primers described before. The pGL3-human bim and pGL3-mutant human bim plasmids were then created by cloning the respective MluI and BglII promoter fragment into the pGL3basic vector (Promega, UK). A similar strategy was used to generate the 795 bp wild-type and mutant mouse bim promoters using the mouse promoter primers: 5 0 -AAGC TTCCCGCCCTCACCCGGGA-3 
Western blot analysis and antibodies
Western blot whole-cell extracts were prepared by lysing cells with four times packed cell volume of lysis buffer (1% Nonidet P-40, 100 mM NaCl, 20 mM Tris-HCl pH 7.4, 10 mM NaF, 1 mM Na 3 VO 4 and protease inhibitors 'Complete' purchased from Roche) on ice for 15 min. Protein yield was quantified by Bio-Rad Dc protein assay kit (Bio-Rad). Lysate (50 mg) was separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes (Protan, Schleicher&Schuell) and specific proteins were recognized by specific antibodies. The antibodies against Bim and c-Abl were purchased from Calbiochem, anti-cleaved caspase 3 (Asp175) was from Cell Signalling, anti-FoxO3a, anti-phospho-FoxO3a (Thr32) and (Ser256) and anti-Bcl-XL were from Upstate Biotechnology, and anti-Lamin B (c-20) was from Santa Cruz. The b-tubulin antibody was acquired from PharMingen. The antibodies were detected using horseradish peroxidase-linked goat anti-mouse or anti-rabbit IgG (Dako), and visualized by the enhanced chemiluminiscent (ECL) detection system (Amersham Biosciences, UK).
RNA isolation and analysis
Total RNA was isolated using the RNeasy Kit (Qiagen), and the concentration and purity of each sample were assessed by absorbance at 260 nm and by the 260/280 nm ratio, respectively. The integrity of the RNA was verified by observing the rRNA bands in ethidium bromide-stained gel under UV irradiation. In all, 20 mg of RNA, prepared as above, was resolved on 1.5% formaldehyde-agarose gels. Following electrophoresis, RNA were transferred to Hybond-N membrane (Amersham Biosciences) and subjected to Northern blotting as previously described (Lam and Watson, 1993) . Bim and GAPDH mRNAs were detected using 32 P-labelled human cDNA probes described previously Dijkers et al., 2002) . The probes were labelled with ReadyTo-Go DNA Labelling Beads (Amersham Biosciences), and purified with ProbeQuant G-50 Micro Columns (Amersham Biosciences).
Transfection and promoter assay
A total of 15 Â 10 6 BV173 or BaF3/Bcr-Abl cells were resuspended in 500 ml of RPMI 1640 medium containing 10% FCS, 2 mM L-glutamine, antibiotics, and 10 mg of reporter plasmid DNA, plus 1 mg of pRLTK Renilla plasmid (Promega) as a transfection control. After a 5 min incubation, cells were electroporated by using a Bio-Rad Gene Pulser (Bio-Rad Laboratories, CA, USA) at 350 V and 950 mF. Cells were then transferred to 10 ml of RPMI 1640 medium and left to recover for 24 h before treatment. Then, cells were harvested, washed with PBS and lysed in 100 ml of Passive Lysis Buffer (Promega) for 5 min at room temperature (RT); after one freeze-thaw cycle, insoluble cell debris was spun down in a microcentrifuge for 1 min, and the supernatant fraction was assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega).
Extraction of DNA-binding proteins
DNA-binding protein extracts from BV173 cells were prepared essentially as described in Andrews and Faller (1991) . Briefly, 25 Â 10 6 cells were centrifuged at 4000 g for 10 min at 41C, washed with ice-cold PBS, and resuspended in 400 ml cold lowsalt buffer A (10 mM HEPES-KOH, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT and 0.2 mM ABSF) by gently flicking the tube. The cells were allowed to swell on ice for 10 min. After a brief vortex, samples were centrifuged for 2 min at 41C, and the supernatant fraction was discarded. The pellet was then resuspended in 30-40 ml cold high-salt buffer C (20 mM HEPES-KOH, pH 7.9, 25% v/v glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT and 1 mM phenylmethyl sulphonyl fluoride (PMSF)) and incubated on ice for 20 min for high-salt extraction. Cellular debris was removed by centrifugation (13 000 g, 2 min, 41C). The supernatant fraction contains the DNA-binding proteins. Protein yield was quantified by Bio-Rad Dc protein assay kit (Bio-Rad).
ChIP assay
BV173 cells cultured at 1 Â 10 6 cells per ml of media were either untreated or treated with 5 mM STI571 for 4 and 8 h, and then collected by centrifugation and resuspended in 10 ml of cold PBS. After adjusting to a final formaldehyde concentration of 1% (w/v), the cells were incubated for 10 min at 371C, followed by the addition of glycine to 0.136 M and incubation for 10 min. After washing with cold PBS, the cells were sonicated in six times 10 s pulses at maximum power in 300 ml Sonication Buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), 1 mM PMSF and 1 Â protease inhibitor cocktail (Roche)). The supernatant was cleared by centrifugation at 13 000 g and diluted 5 times with Sonication Buffer, of which one-tenth was retained as input control. DNA shearing was controlled by running part of the sonicated chromatin on an agarose gel to ensure that fragmented DNA is of 200-500 bp. To preclear the chromatin solution, 2 mg of sonicated single-strand herring sperm DNA (Sigma) and 45 ml of a 50% (v/v) slurry of Protein G-sepharose (Pharmacia) beads were added to the rest of the sample. After incubation with agitation for 30 min at RT, the beads were removed by brief centrifugation and the supernatant collected. The retrieved supernatant was either incubated with the anti-FoxO3a antibody (Upstate) or an isotype control antibody (Babco) for 2 h at RT with rotation in the presence of 2 mg of sonicated singlestrand herring sperm DNA (Sigma) and 45 ml of a 50% (v/v) slurry of Protein G-sepharose (Pharmacia) beads. The beads were then washed sequentially with PBS, Sonication Buffer, TSE I, II and III, and PBS as described previously by Braunstein et al. (1993) . The immunoprecipitated DNA (or the input control) was extracted with 300 ml of extraction solution (1% SDS and 1.1 M NaHCO 3 ), incubated at 651C for 6 h to reverse the crosslinks, and purified using the Qiagen PCR Purification Kit according to the manufacturer's protocol. PCRs were then performed on the purified DNA, according to the Qiagen Taq PCR Handbook, in the presence of 2.5 mM MgCl 2 , at 551C, for 28 cycles, using the following primers: primer A forward (À421/À401) (5
. Analysis of the PCR products was performed on a standard 2% (w/v) agarose gel, by electrophoresis in Tris-acetate EDTA buffer.
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Cell cycle phase analysis by propidium iodide staining
Cells were collected and fixed in 90% ethanol in PBS and stored at 41C until cell cycle analysis was carried out. Cells were spun down, washed in PBS and resuspended in a solution of PBS, containing 10 mg/ml propidium iodide (Sigma, Poole, UK), 5 mg/ml of RNase A (Sigma, Poole, UK), and incubated at room temperature for 30 min before FACS analysis is performed using a FACSCanto (Becton Dickinson, Cowley, UK). FACS analysis was performed using the Diva and Cell Quest softwares (Becton Dickinson, Cowley, UK).
Oligonucleotide 'pull-down' assay
Nuclear extracts were prepared from cultured cells using the high-salt buffer as described. After diluting with 2 volumes of low-salt lysis buffer, 50 mg of the cell extracts was incubated at 301C for 10 min with either 0.5 nmol of the 5 0 -biotinylated double-stranded wild-type (5 0 -CAGAGTTACTCCGGTAAA CACGCCAGGGAC-3 0 ) or mutant (5 0 -CAGAGTTACTCCG GTAGGCACGCCAGGGAC-3 0 ) oligonucleotides (Invitrogen) previously coupled to streptavidin agarose beads (Sigma, Poole, UK). All the pull-down experiments were performed with exactly equal aliquots from the same sample of either untreated or STI571-treated nuclear extracts. The wild-type oligonucleotide corresponded to the region of À139 to À145 of the human bim promoter. After incubation, the biotinylated oligonucleotide-coupled streptavidin beads were washed at least 6 times with low-salt buffer containing 150 mM NaCl and denatured in SDS-sample buffer before running on a SDSacrylamide gel. The separated proteins were then Western blotted for FoxO3a using specific antibodies. For competition experiments, the extracts were incubated with the wild-type oligonucleotide-coupled beads in the presence of 1 Â , 10 Â , or 50 Â molar excess of either the wild-type or mutant nonbiotinylated oligonucleotide.
Small interference RNA (siRNA)
The mammalian expression vector pSUPER (Brummelkamp et al., 2002) was used for gene silencing of FoxO3a in BaF3/ Bcr-Abl cells. The gene-specific insert consists of a 19-nucleotide sequence corresponding to nucleotides GACCTGC TTGCTTCAGACT separated by a 9-nucleotide noncomplementary spacer (tctcttgaa) from the reverse complement of the same 19-nucleotide sequence. This construct (10 mg) was transiently transfected in BOSC cells by calcium phosphate coprecipitation. The viral supernatant was harvested 48 h after transfection, filtered and added to BaF3/Bcr-Abl cells. The infected BaF3/Bcr-Abl cells were selected by addition of puromycin (200 mg/ml) to the growth media. After 14 days of selection, cells were expanded and analysed for FoxO3a expression. For silencing of Bim expression, siRNA oligonucleotides purchased from Dharmacon Research Inc. (Lafayette, CO, USA) were transfected into BaF3/Bcr-Abl cells by electroporation as described. Essentially, 15 Â 10 6 cells were collected by centrifugation, resuspended in 500 ml prewarmed complete RPMI medium, and eletroporated using a Bio-Rad Gene Pulser (Bio-Rad Laboratories, Richmond, CA, USA) at 350 V and 950 mF in the presence of 2 mg siRNA oligonucleotides. After electroporation, the cells were transferred immediately into prewarmed complete RPMI medium and left overnight to recover before treatment. The mouse Bim siRNA sequence (nucleotide 46-64 with respect to the translation start site of BimEL) is present in all known Bim mRNA splice forms, but does not match any other sequence, in the GenBank.
Results
Bcr-Abl inhibition by STI571 is associated with dephosphorylation of FOXO3a and accumulation of Bim mRNA and protein
Inhibition of Bcr-Abl kinase by STI571 in various Ph þ cell lines has been shown to lead to apoptosis (Deininger et al., 2001; Parada et al., 2001; Kuribara et al., 2004b) . In order to investigate the mechanism by which STI571 induces cell death in CML, the human lymphoid CML cell line BV173 was treated with STI571 over a time course of 72 h. Analysis of cellular DNA content by propidium iodide staining showed that inhibition of BcrAbl kinase activity by STI571 caused BV173 cells to arrest in G0/G1 phase before undergoing apoptosis. The majority of cells arrested predominantly at G0/G1 by 8 h after STI571 treatment, and apoptosis was evidently observable after 24 h, as revealed by the sub-G1 DNA content. By 72 h, over 30% of the cells displayed detectable sign of apoptosis (oG1 DNA content). Since the proapoptotic BH-3 only protein Bim has been implicated in the apoptosis induced by STI571 in CML, we studied the expression of Bim in this cell system by Western blotting. The results showed that the levels of all three isoforms, BimEL, BimL and BimS, increased in response to STI571 (Figure 1b) . Subsequent Northern blot analysis demonstrated that this increase in Bim expression also occurred at transcriptional level ( Figure 1c ). It is notable that there was a reduction in Bim and 28 s RNA at 24 h. This is most probably the result of degradation of RNA due to apoptosis induced by STI571. Previous data from other cell systems have suggested that Bim is a downstream target of FoxO transcription factors. To explore if FoxO could be involved in the induction of Bim expression in response to STI571, Western blot analysis was carried out to study the expression pattern and activity of FoxO proteins (Figure 1b) . The result showed that FoxO3a transcription factor was constitutively phosphorylated at the PKB-targeted sites (e.g. Thr32 and Ser253) in untreated cycling BV173 cells, and that the induction of Bim expression by STI571 was associated with dephosphorylation of FoxO3a 1 h after STI571 addition. Notably, the FoxO3a level also increased moderately after STI571 treatment, and that expression of other FoxO family members was not detectable at significant levels (data not shown). The expression of tubulin was used as a loading control and shown to be unchanged. We also used an antibody (Asp175) which specifically recognizes the cleaved (active) forms of caspase 3 to gauge the levels of apoptosis. The Westerm blot result showed that the cleaved caspase 3 was first detectable at 24 h after STI571 treatment (Figure 1b) , consistent with the finding from propidium iodide staining. These results suggested the possibility that the transcription factor FoxO3a could be responsible for Bim induction by STI571 to mediate cell death in CML cells.
STI571 and FoxO3a induces Bim expression through a FoxO site located in its promoter
In order to examine if STI571 and FoxO3a activate Bim expression at promoter level and to identify the transcriptional element(s) involved, we set out to clone the bim promoter. A 3.5 kbp mouse bim promoter was previously identified (Bouillet et al., 2001) , and deletion analysis showed that the activity of the promoter is completely retained in the 700 bp region upstream of the transcriptional start site. Based on this information, we cloned by PCR the mouse bim promoter (795 bp) and the equivalent human promoter (785 bp). Figure 2a depicts the alignment of the putative mouse and human bim promoters. Sequence analysis of the human and mouse promoter regions showed 61% identity and a number of common putative transcription factor-binding sites. Among these is a potential FHRE (Forkhead responsive element) proximal to the transcription start site, which can be involved in the induction of Bim by STI571 and FoxO3a. This FHRE is also conserved in the rat sequence and has been shown to be responsive to FoxO3a induction in neuronal cells (Gilley et al., 2003) .
To determine if the upregulation of Bim expression by STI571 occurs at the gene promoter level, we examined the effect of STI571 on the wild-type human bim promoter construct after transfection into BV173 cells. As shown in Figure 2c , the wild-type human bim promoter activity was induced by STI571 treatment. Importantly, deletion of the FHRE effectively abrogated the effects of STI571 on the promoter, indicating that STI571 mediates the transactivation of the bim promoter through the proximal FoxO-binding site. Furthermore, the kinetics for the induction of bim promoter activity correlated with the observed increase in mRNA level, suggesting transcriptional control of the bim promoter by STI571. Interestingly, the basal promoter activity of the wild-type bim promoter was more than 10-fold higher than that of the mutant construct, which lacks the FHRE. To examine the role of the FoxO3a transcription factor in the regulation of Bim expression, we transiently transfected BV173 cells with expression vectors encoding the wild-type FoxO3a (FoxO3a-wt) or a nonphosphorylatable constitutively active mutant (FoxO3a-A3), together with either the wild-type or mutant human bim promoter (Figure 2d ). The result demonstrated that activity of the wild-type, but not the mutant, bim promoter was inducible by both the wild-type and active forms of FoxO3a in a dose-dependent manner. Notably, the wild-type and active forms of FoxO3a have similar effects on the human bim promoter. Since cotransfection is an overexpression-based study, it is likely that the level of wild-type FoxO3a in the small number of transfected cells far exceeds that of the active PKB, thus accounting for the transactivation activity of the wild-type FoxO3a. Together, these tranfection data indicated that the induction of Bim expression by STI571 occurs at gene promoter level, and that the proximal FoxO site mediates the promoter's response to STI571 and FoxO3a.
STI571 induces direct binding of FoxO3a to the FHRE at the bim promoter
In order to demonstrate physical interaction of FoxO3a with the FHRE of the human bim promoter, we used biotinylated double strained oligonucleotides coupled to streptavidine agarose beads to 'pull-down' proteins interacting with the FHRE in BV173 cells in the absence or presence of 4 h STI571 treatment. The bound protein complexes were then analysed by Western blotting (Figure 3) . The result showed that FoxO3a bound to the wild-type FHRE oligonucleotide but not to a similar oligonucleotide with the FHRE mutated. The result also showed that STI571 treatment increased the binding of FoxO3a to the FHRE. Further Western blot analysis of the input nuclear extracts showed that the increase in 
binding of FoxO3a to the FHRE is predominantly the result of an increase of FoxO3a level in the nucleus following STI571 treatment. This interaction depends on the FHRE, as the FoxO3a binding could be competed off using increasing amounts of an oligonucleotide containing the FoxO site, but not a similar oligonucleotide with the FHRE mutated. These results strongly suggest that FoxO3a is recruited directly to the FHRE of the bim promoter upon STI571 treatment.
FoxO3a is recruited to the proximal region of the Bim promoter in vivo in response to STI571
We next performed chromatin immunoprecipitation (ChIP) assays to determine the in vivo occupancy of the bim promoter in response to STI571. As demonstrated in Figure 4 , the anti-FoxO3a antibody, but not the control antibody (IgG), precipitated the region of the bim promoter containing the FoxO site in BV173 Transcriptional regulation of Bim by FoxO3a and Bcr-Abl A Essafi et al cells. The amount of precipitated DNA by anti-FoxO3a increased significantly following treatment with STI571 for 4 and 8 h. This result suggested an increased binding of FoxO3a to this bim promoter region in vivo in response to STI571, consistent with the DNA pull-down results. To control for DNA shearing, we also carried out ChIP anlysis using the anti-FoxO3a antibody on two other bim promoter regions, one about 1 kbp upstream and the other 1 kbp downstream of the FoxO site. As depicted in Figure 4 , the anti-FoxO3a failed to precipitate any of these gene fragments in the absence or presence of STI571 treatment. This result confirms the findings from the transfection and pull-down experiments, demonstrating that STI571 induces the accumulation of active FoxO3a on the bim promoter to activate its transcription.
Induction of FoxO3a induces Bim expression and apoptosis
The BV173 cell lines are intrinsically resistant to efficient transfection for production of stable permanent transfectants. To further confirm the results obtained in BV173 cells, we used a murine Bcr-Abl-transduced BaF3 cell line (BaF3/Bcr-Abl) expressing a 4-hydroxytamoxifen (OHT)-inducible FoxO3a-A3 construct, BaF3/Bcr-Abl Á FoxO3a(A3):ER (Dijkers et al., 2000a) , Figure 2 Characterization of the human bim promoter and its activity after STI571 treatment in BV173 cells. (a) Nucleotide sequence of the 0.8 kbp fragment of the mouse bim promoter aligned to the corresponding human sequence using Needleman-Wunsch method (Nussinov, 1983) . The sequence is numbered with the first nucleotide of the transcription start site indicated as þ 1 (corresponding to position 78361 of GenBank Accession Number AC096670). The putative cis-acting transcription factor binding sites are represented in boxes with only the FoxO (FHRE) and one Sp1 site being conserved in both promoters. The shaded sequence represents the most 5 0 -sequence of the known cDNA. (b) Schematic representation of the human bim promoter (0.8 kbp) showing the mutation introduced in the FoxO consensus site. (c) Comparison of relative luciferase activity between the human wild-type (WT) and mutant (mut) bim promoters. BV173 cells were transiently transfected with the pGL3-humanbim WT or pGL3-humanbim mut promoter constructs (10 mg), and incubated the day after with STI571 for 24 h. Cells were harvested and assayed for luciferase activity. All values were corrected for cotransfected renilla activity. The normalized luciferase activity was compared between the wild-type and mutant promoters in the untreated cells (left panel). The luciferase activity of the pGL3-humanbim WT or pGL3-humanbim mut promoters were monitored over 24 h and expressed as fold of induction by STI571 treatment compared with the nontreated conditions (right panel). (d) BV173 cells were transiently transfected with the pGL3-humanbim WT or mut promoter constructs (10 mg), together with increasing amounts (0, 1, 5 and 10 mg) of pLPCFoxO3a WT or A3. Cells were harvested 24 h after transfection and assayed for luciferase activity. Values are corrected for cotransfected renilla activity. All data shown represent the average of three independent experiments, and the error bars show the standard deviation Sequence of the 30 bp oligonucleotides containing the FoxObinding site of the human Bim promoter used in this study. The oligonucleotides were generated with 5 0 ends either free or conjugated to biotin molecules. Also shown is the mutation introduced in the FoxO responsive element for the mutant oligonucleotides (the middle nucleotides TT being substituted with GG). DNA-binding protein extracts were prepared from BV173 cells 8 h after STI571 treatment. The extracts were incubated with 1 mg of biotin-conjugated oligonucleotides (mut in the first two lanes and WT in all other lanes). In lanes 5, 6, 7 and lanes 8, 9, 10 increasing amounts (1, 5, 50 mg) of competing nonconjugated oligos were incubated with the mix. SDS-PAGE immunoblot analysis of the washed lysates was performed using specific antibodies against anti-FoxO3a. The input nuclear extracts were also subjected to Western blot analysis for FoxO3a and Lamin B expression (Figure 5b ). This effect was evident as early as 2 h after addition of the drug. In contrast, addition of 4-OHT had no effect on the expression of Bim in the BaF3/Bcr-Abl cells during the 24 h time course. When cleaved caspase 3 was analysed, the result showed a significant increase in cleaved caspase 3 in BaF3 Á Fox O3a(A3):ER cells after addition of 4-OHT, indicating that FoxO3a activation induces apoptosis in the BaF3/ Bcr-Abl cells. The cleaved caspase 3 was detectable at low levels in the control BaF3/Bcr-Abl cells. This could be due to the consequence of high cell density or prolonged incubation with 4-OHT. Expression of FoxO3a-ER in the BaF3 Á FoxO3a(A3):ER cell line was confirmed by Western blotting using a FoxO3a antibody. Tubulin levels were analysed to confirm equal loading. These results provide strong in vivo evidence for regulation of Bim expression and induction of apoptosis by FoxO3a.
Silencing of FoxO3a abrogates induction of Bim and apoptosis by STI571 in BaF3/Bcr-Abl cells
To further confirm the role of FoxO3a in Bcr-Abl signalling and Bim induction, we used the pSUPER system to stably suppress the expression of FoxO3a. BaF3/Bcr-Abl cells were transduced with the pSUPERFoxO3a construct or the empty pSUPER vector, and puromycin-resistant cells were expanded and analysed for FoxO3a expression. As illustrated in Figure 6b , the pSUPER-FoxO3a-expressing cells showed a complete silencing of FoxO3a expression. Flow cytometric analysis cells revealed that STI571 treatment of the control BaF3/Bcr-Abl cells for 24 h induced cell cycle arrest and apoptosis (Figure 6a ). By contrast, the cell cycle arrest and apoptosis were inhibited in cells expressing the pSUPER-FoxO3a vector, highlighting the biological relevance of FoxO3a in Bcr-Abl signalling. In order to assess the molecular effects of FoxO3a silencing, cells were treated with STI571 for various times, and analysed for the expression of FoxO3a and Bim. As seen in Figure 6b to STI571 treatment. To this end, we transfected the wild-type and the FHRE-mutant mouse promoters into the control and pSUPER-FoxO3a-expressing BaF3/ Bcr-Abl cell lines, and assayed for the ability of STI571 to induce the promoter activity under different conditions over 24 h (Figure 7) . The results indicated that whereas the wild-type bim promoter was inducible by STI571, the FKRE-mutated promoter was refractory to STI571 induction in the parental BaF3/Bcr-Abl cells, confirming the results obtained from the human BV173 cells. In the BaF3/Bcr-Abl cells expressing the pSUPERFoxO3a construct, both the wild-type and the mutant promoters were insensitive to STI571 induction. Interestingly,the basal activity of the wild-type bim promoter was marginally higher than that of the FKRE-mutated promoter. The significance of this is unclear; however, it could reflect the possibility that low levels of residual Forkhead activity exists in the BaF3/Bcr-Abl (FoxO3a siRNA) cells. Together, these gene silencing results confirmed Bim as a transcriptional target of FoxO3a in vivo.
Silencing of Bim suppresses apoptosis induced by STI571 in Bcr-Abl-expressing cells
To establish the role of Bim in the STI571-induced apoptosis, we performed gene silencing experiments of Bim in BaF3/Bcr-Abl cells. To this end, cells were transfected with siRNA specific for all known Bim transcripts and then treated with STI571 for 24 h. As controls, the BaF3/Bcr-Abl cells were either nontransfected or transfected with an irrelevant siRNA. Propidium iodide staining demonstrated that the nontransfected BaF3/Bcr-Abl cells and those transfected with the control siRNA underwent apoptosis in response to STI571 treatment, while the cells transfected with the Bim siRNA were largely protected from the drug (Figure 8a ). Western blotting result clearly showed an induction of Bim expression in the nontransfected cells and cells transfected with the control siRNA following STI571 treatment (Figure 8b ). However, in the cells transfected with the siRNA against Bim, a significantly lower level of Bim induction was observed after exposure to STI571. Importantly, silencing of Bim induction by siRNA transfection resulted in the effective abrogration of the STI571-mediated cleavage of caspase 3, confirming the findings from the propidium iodide staining. Together, these results establish Bim as a direct trancriptional target of FoxO3a and show that Bim and FoxO3a mediate the apoptotic function of STI571 in Bcr-Abl-expressing cells.
Discussion
Previously, using CML-derived cell lines and the BcrAbl-transformed mouse pro-B BaF3 (BaF3/Bcr-Abl) cells, we have demonstrated that the PI3-K pathway is constitutively activated by the Bcr-Abl tyrosine kinase and that the anti-Bcr-Abl kinase drug STI571 downregulates the PI 3-K and PKB activities to induce cell cycle arrest and apoptosis (Deininger et al., 2001; Parada et al., 2001) . FoxO transcription factors are direct targets of PKB, a serine/threonine kinase that functions downstream of the PI3-K proliferative and survival pathway. Modulation of FoxO activity has been proposed to be a key mechanism for regulating apoptosis and cell cycle progression in haematopoietic progenitor cells. In concordance with these earlier work, we show here that FoxO3a is constitutively phosphorylated at the PKB-targeted sites in Bcr-Abl-expressing cell lines, and this phosphorylation is inhibited upon treatment with STI571. In addition, we also consistently observed an upregulation of total FoxO3a expression in response to STI571, suggesting that STI571 induces FoxO3a activity not only by inhibiting its phosphorylation status but also by increasing its expression level. The exact mechanism for this FoxO3a induction is unknown; however, previous studies have indicated that the turnover of FoxOs can also be modulated by ubiquitination-mediated degradation, and this mechanism can contribute to the upregulation of Fox3a expression by STI571 in Bcr-Abl-expressing cells. The induction of FoxO3a activity by STI571 in both the human BV173 and the mouse BaF3/Bcr-Abl cells is accompanied by cell cycle arrest followed by apoptosis. These findings are consistent with recent reports proposing that STI571 targets FoxO3a to induce cell cycle arrest and apoptosis in Bcr-Abl-transformed cell lines (Ghaffari et al., 2003; Komatsu et al., 2003) . Our previous studies of Bim-deficient mice demonstrated that Bim null haematopoietic progenitors are more resistant to apoptosis induced by cytokine-withdrawal or PI3-K inhibition . A recent report also showed that the proapoptotic Bcl-2 family protein Bim has a major role in mediating apoptosis of normal and Bcr-Abl-expressing haematopoietic progenitors (Kuribara et al., 2004a) . In line with these findings, we observed that the STI571-induced apoptosis is preceded by an accumulation of all three isoforms of Bim, BimEL, BimL and BimS in both BV173 and BaF3/Bcr-Abl cells. We also showed by Northern blot and transient transfection analyses that Bim is upregulated by STI571 at mRNA and gene promoter levels in a similar kinetics as the protein, indicating that STI571 transcriptionally upregulates Bim expression to promote cell death. Examination of the mouse and human bim promoter regions revealed a conserved putative FHRE located upstream of the transcription start site. These findings together suggest the possibility that STI571 activates bim expression via FOXO3a to mediate apoptosis in Bcr-Abl-expressing cells.
Bim has been implicated as a downstream target of FoxOs, but the exact relationship between these two apoptotic regulators has not been clearly established. There was no definitive information available on the molecular mechanism by which FoxOs mediate Bim expression, and it was not clear if Bim is a direct or indirect target of FoxO3a. Djikers et al. (2000b) have previously showed that activation of FoxO3a-ER fusion protein in the presence of cycloheximide can induce Bim expression. However, this experiment, on its own, only indicates that FoxO3a can induce Bim expression in the absence of protein synthesis and cannot definitively prove that Bim is a direct transcriptional target of FoxO3a. Similarly, Gilley et al. (2003) have demonstrated that FoxO3a can transactivate the rat bim promoter via a putative FHRE, yet no data are available to show that endogenous FoxO3a binds directly to the bim promoter in vivo. Using the Bcr-Abl-positive haematopoietic cell systems, we obtained data demonstrating that Bim is a direct transcriptional target of FoxO3a. Our transfection studies of the human and mouse bim promoters showed that the FHRE is responsible for its induction by STI571 and FoxO3a, as mutation of this site renders the bim promoter insensitive to STI571 and FoxO3a. The fact that the basal promoter activity of the wild-type bim promoter is more than 10-fold higher than that of the mutant indicates that FoxO is essential for Bim expression. Moreover, the DNA 'pull-down' results indicated that FoxO3a binds directly to an FHRE located in its promoter proximal to the transcription start site and that this binding is augmented by STI571 treatment. We further confirmed the in vivo occupancy of the bim promoter by FoxO3a by chromatin immunoprecipitation analysis and showed that FoxO3a protein is recruited to the endogenous bim promoter in BV173 cells in response to STI571 treatment.
The hypothesis that STI571 induces apoptosis through Bim and FoxO3a is validated by a number of lines of evidence. First, induction of FoxO3a activity by tamoxifen in the murine BaF3/Bcr-Abl Á FoxO3a(A3): ER cell line causes the upregulation of Bim and apoptosis in vivo. Second, silencing of FoxO3a expression by the pSUPER siRNA system abolishes the STI571-mediated induction of apoptosis and the upregulation of endogenous Bim expression at protein, mRNA and gene promoter levels. Third, gene silencing of FoxO3a also blocks the induction of the bim promoter by STI571 in BaF3/Bcr-Abl cells. In addition, knocking-down of endogenous Bim by specific siRNA in BaF3/Bcr-Abl cells abrogates apoptosis following STI571 treatment, further demonstrating the role of Bim as a mediator of the survival signal emanating from BcrAbl. Interestingly, although apoptosis is blocked by the depletion of Bim in these BaF3/Bcr-Abl cells, they still arrest predominantly at the G1 phase of the cell cycle following STI571 treatment. This highlights the fact that these BaF3/Bcr-Abl cells are responsive to STI571 treatment and underscores the apoptotic function of Bim in Bcr-Abl signalling. Besides being regulated at transcriptional level by FoxOs, Bim has also been shown to be negatively controlled by phosphorylation (Biswas and Greene, 2002; Seward et al., 2003) and ubiquitination-mediated turnover (Akiyama et al., 2003; Ley et al., 2003 Ley et al., , 2004 Luciano et al., 2003) . We have not determined in this study whether these post-translational mechanisms also contribute towards the apoptosis induced by STI571. Nevertheless, our results have provided clear evidence that transcriptional induction of Bim by FoxO3a is a key mechanism by which STI571 triggers cell death in Bcr-Abl-positive cells.
Bim binds to the antiapoptotic Bcl-2 members, including Bcl-xL and Bcl-2, and thereby, inhibits their survival function (Strasser et al., 2000) . This will result in release of cytochrome c from the mitochondria to the cytosol to activate the apoptosis-inducing caspase cascades. Another FoxO family member FoxO4 has previously been shown to repress indirectly the transcription of the antiapoptotic Bcl-2 family member BclxL through activation of the transcriptional repressor Bcl-6 (Tang et al., 2002) . Recently, we have also reported that FoxO3a and Bcr-Abl regulate cyclin D2 transcription through a Bcl-6-binding site located in the cyclin D2 promoter via a similar mechanism (Ferna´ndez de Mattos et al., 2004) . It is therefore conceivable that, in addition to the transcriptional activation of Bim reported here, induction of FoxO3a activity by STI571 may also repress the expression of Bcl-xL indirectly via Bcl-6 to promote apoptosis. However, arguing against this possibility is the observation that STI571 has only minimal effects on Bcl-xL expression in BV173 cells.
In summary, the present report establishes the molecular mechanism by which the anti-Bcr-Abl kinase drug STI571 induces Bim expression and apoptosis. Together, the results presented here clearly confirm FoxO3a as a key regulator of Bim expression and apoptosis, and establish FoxO3a as responsible for Bim induction by STI571. Our data also show that bim is a direct target gene of FoxO3a. Thus, STI571 treatment induces an accumulation of FoxO3a activity which in turn binds directly to an FHRE conserved in the mouse and human promoter to activate Bim expression and apoptosis.
Abbreviations CML, chronic myelogenous leukaemia; Ph, Philadelphia chromosome; PI 3-K, phosphatidylinositol 3-kinase; PKB, protein kinase B; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate-buffered salin; 4-OHT, 4-hydroxytamoxifen; RT, room tempertaure.
